Company profile
Revvity, Inc.
NYSE: RVTY · Healthcare · Medical - Diagnostics & Research
#91 of 1,418 Healthcare companies by revenue47th-percentile growth
EA Score
79B+FH 82DQ 91GM 36SS 97
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ growth stability, 3-yr revenue growth
Methodology →Revenue TTM
$2.9B
Rev growth YoY (TTM)
+4.8%
Net income (FY)
$241.2M
Employees
11,000
as of 2026-09-06
Market cap
$14.5B
as of 2026-09-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.9B$2.9B2025
Net income$241.2M$241.2M2025
Operating income$356.6M$356.6M2025
Total assets$12.2B$12.2B2025
Liabilities$4.9B$4.9B2025
Equity$7.3B$7.3B2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Life Sciences50%
Diagnostics50%
By geography
Other International60%
UNITED STATES25%
CHINA9%
GERMANY4%
UNITED KINGDOM3%
The read
What is Revvity, Inc.’s revenue?
Revvity, Inc. booked $2.9B in FY2025 revenue, growing 3.7% year over year — about the middle of the pack among Healthcare companies we track, at a 8.4% net margin.
Peers · Healthcare
Amneal Pharmaceuticals, Inc.75B+Globus Medical, Inc.86ANeurocrine Biosciences, Inc.88AModivCare Inc.——Accendra Health, Inc.62CAMN Healthcare Services, Inc.70BNeighbors
Middlesex →Key facts
CEOPrahlad R. Singh
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersWaltham, MA
ExchangeNYSE: RVTY
Employees11,000
IPO date1965-07-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.